Choose the low-profile DCB with trusted technology.

IN.PACT™ 018 DCB combines a low-profile design and proven technology to deliver lasting results to your patients with femoropopliteal disease. 

Engineered to cross tight lesions up to 360 mm long, including in-stent restenotic lesions

5 Fr compatible
(4–6 mm diameter)

130 and 200 cm catheter lengths provide the option of transradial† or femoral access.

Uses the same proven formulation as IN.PACT™ Admiral™ DCB

Proven formulation of paclitaxel in tissue

Only IN.PACT™ DCBs release the drug into the tissue through the restenotic window, which is the time period the vessel is at the highest risk of narrowing again.

Duration of paclitaxel in tissue‡

‡ Data comes from different individual studies and may differ in a head-to-head comparison and therefore may not be predictive of clinical results.

Versatile portfolio, trusted data

The Medtronic IN.PACT™ 018 and IN.PACT™ Admiral™ DCBs allow you to choose your preferred tool, knowing you‘re using DCBs backed by unmatched safety and efficacy data5 — including five-year data on complex lesions.6

With 75% of patients remaining reintervention-free at five years,5 IN.PACT™ Admiral™ has:

  • Demonstrated a statistically significant delta versus PTA for primary patency at three years§,5
  • Demonstrated a statistically significant delta versus PTA for freedom from CD-TLR at five years5
  • More than 30 sponsored publications7
See the data

The safety and effectiveness of the IN.PACT™ Admiral™ DCB (0.035" guidewire compatible), as established in the clinical studies that were performed primarily via femoral access, can be considered supportive for the IN.PACT™ 018 DCB. The IN.PACT™ 018 DCB has not been evaluated in a clinical study.

Unique mechanism of action

IN.PACT™ DCBs use a proprietary combination of paclitaxel drug and the excipient, urea, to allow for rapid transfer of the antiproliferative drug to the vessel wall.

Watch this mechanism of action animation to see what makes IN.PACT™ DCBs unique.

Risks may include: access site pain or infection, hemorrhage, local or distal embolic events, perforation or rupture of the artery, amputation and death.

Clinical case review

Watch Dr. Jun Li, Dr. Peter Monteleone, and Dr. Sameh Sayfo discuss challenging cases where IN.PACT™ 018 DCB was used after vessel preparation.

The physician panel also discusses:

  • Treating the SFA and popliteal via radial† access using IN.PACT™ 018 DCB‘s 200 cm catheter
  • Use of directional atherectomy followed by DCB
  • Impact of paclitaxel safety on physician practices

Outcomes protection program

Backed by proven technology, the IN.PACT™ Admiral™ and IN.PACT™ 018 DCB Outcomes Protection Program is one of the ways we are partnering with you to improve patient outcomes, manage costs, and advance value-based healthcare.

We’re so confident in our clinical outcomes that we will share in the cost of care if your patients require reintervention within one year of treatment.

Learn more (open in new window)

Treat

Treat your patient with IN.PACT™ Admiral™ DCB or IN.PACT™ 018 DCB according to the IFU.

Qualifying event

If your patient returns for a qualifying reintervention within one year, your facility is eligible for a rebate.

Rebate

Simply submit the claim form within 30 days of the secondary intervention, and Medtronic will provide a $1,000 rebate to share in the cost of care. 

Features

  1. Platinum-iridium marker bands
  2. Coaxial shaft
  3. FreePac™ coating
  4. 130 and 200 cm catheter lengths

Peel-away balloon protector

The IN.PACT™ 018 DCB features a peel-away balloon protector that helps preserve the integrity of the drug coating.

See size matrix

Additional resources

Reach a Medtronic sales representative.

Connect with us

Contact information

Orders
763-514-8510
rs.cuvasorders@medtronic.com

Cardiovascular Lifeline Technical Services
763-526-7890
rs.cstechsupport@medtronic.com

24-hour technical support (worldwide)
763-514-4000